• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Topics » General Psychiatry » Files

General Psychiatry

RAMELTEON (Rozerem) Fact Sheet [G]

November 29, 2023

Ramelteon is a melatonin receptor agonist. Compared to other hypnotics, ramelteon poses a lower risk for respiratory depression and hangover effect (morning grogginess). It’s a good agent to have in your bag of tricks, but consider the possibility of rare hormonal effects. Also consider that over-the-counter melatonin (which ramelteon mimics) may do the same job, possibly at a lower price. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

CLOZAPINE (Clozaril, FazaClo, Versacloz) Fact Sheet [G]

November 29, 2023

Clozapine is the only drug with convincing evidence of superior efficacy over other antipsychotics for treatmentresistant schizophrenia. Consider using it after two failed trials of other antipsychotics. Side effects can be a real challenge, including severe weight gain, constipation, drooling, sedation, and potential neutropenia. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

TESTOSTERONE (various) Fact Sheet [G]

November 29, 2023

Successful marketing has convinced the public that “low T” is a public health scourge, leading to over-prescribing of testosterone for patients who don’t need it. Prescribe it only for men with demonstrably low testosterone levels and accompanying symptoms. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

TRIFLUOPERAZINE (Stelazine) Fact Sheet [G]

November 29, 2023

Trifluoperazine, like thiothixene (Navane), is an effective older agent with similar potency to haloperidol or fluphenazine; however, given all our antipsychotic options, it sees only rare use these days. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

Vagus Nerve Stimulation (VNS) Fact Sheet

November 29, 2023

The efficacy of VNS remains too controversial to recommend its use in all but the most desperate clinical situations. Noninvasive VNS devices may become available for depression treatment in the future. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

SERTRALINE (Zoloft) Fact Sheet [G]

November 29, 2023

Sertraline is a good first-line SSRI option for many patients due to its range of indications, flexible dosing, low drug interaction potential, and relative tolerability. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

VALPROIC ACID (Depakene, Depakote, others) Fact Sheet [G]

November 29, 2023

Valproic acid is the go-to antimanic agent for acute manic episodes, featuring faster onset of response and better adverse effect profile compared to lithium, fewer drug interactions than carbamazepine, and efficacy for rapid cycling and relapse prevention. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

BREXANOLONE (Zulresso) Fact Sheet

November 29, 2023

Brexanolone is a novel, fast-acting option that is given intravenously for patients with severe postpartum depression. However, its utility is limited by the lengthy infusion (60 hours) in a health care setting, potential for severe reactions and associated need for close monitoring, high cost ($34,000 for the drug alone, plus costs associated with providers and health care facilities), and lack of follow-up data beyond 30 days. Zuranolone, a new orally available neurosteroid, provides a safer and easier option for this indication. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

SUVOREXANT (Belsomra) Fact Sheet

November 29, 2023

Suvorexant is an orexin receptor antagonist, and as such it treats insomnia differently from existing agents (though lemborexant and daridorexant have since followed in its footsteps). Other than a new mechanism of action, suvorexant doesn’t have any clear advantages. It is no more effective than benzos or Z-drugs, and it has a similar abuse liability. We’re concerned that next-day impairment is a potential side effect at the highest approved dose of 20 mg, particularly since sleepless patients may decide on their own to take even higher doses. It’s not a first-line hypnotic. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

CLONAZEPAM (Klonopin) Fact Sheet [G]

November 29, 2023

Due to its longer half-life, clonazepam causes fewer breakthrough symptoms compared to alprazolam when used for anxiety. May also work as a good short-term hypnotic, although development of dependence and long half-life limit this use. From Medication Fact Book for Psychiatric Practice, 7th Edition (2023).

Previous 1 2 … 22 23 24 25 26 27 28 29 30 Next
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • HospPsychiatry_Spiral_Binding_Sm.png

    Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

    This comprehensive guide is designed to be a valuable resource for professionals working in...
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2603816031.jpg
    General Psychiatry

    A Scam for Every Woman, Child, and Man: Part 2

    1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.